US Bancorp
CHRS icon

US Bancorp’s Coherus Oncology CHRS Stock Holding History

US Bancorp’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,001
Closed -$2.42K – 4182
2025
Q1 		$2.42K Hold
3,001
– – ﹤0.01% 3835
2024
Q4 		$4.14K Hold
3,001
– – ﹤0.01% 3696
2024
Q3 		$3.12K Hold
3,001
– – ﹤0.01% 3688
2024
Q2 		$5.19K Buy
+3,001
New +$6.04K ﹤0.01% 3501
2023
Q4 		– Sell
-260
Closed -$972 – 3996
2023
Q3 		$972 Buy
+260
New +$1.2K ﹤0.01% 3769
2023
Q2 		– Sell
-285
Closed -$1.95K – 4010
2023
Q1 		$1.95K Sell
285
-1,000
-78% -$7.76K ﹤0.01% 3762
2022
Q4 		$10.2K Sell
1,285
-43
-3% -$331 ﹤0.01% 3293
2022
Q3 		$13K Buy
1,328
+43
+3% +$435 ﹤0.01% 3253
2022
Q2 		$9K Sell
1,285
-2,083
-62% -$18.1K ﹤0.01% 3386
2022
Q1 		$44K Sell
3,368
-473
-12% -$6.01K ﹤0.01% 2690
2021
Q4 		$61K Buy
3,841
+400
+12% +$7K ﹤0.01% 2541
2021
Q3 		$55K Sell
3,441
-1,965
-36% -$28.8K ﹤0.01% 2596
2021
Q2 		$75K Buy
5,406
+2,566
+90% +$36.3K ﹤0.01% 2461
2021
Q1 		$41K Hold
2,840
– – ﹤0.01% 2677
2020
Q4 		$49K Hold
2,840
– – ﹤0.01% 2517
2020
Q3 		$52K Buy
2,840
+215
+8% +$4K ﹤0.01% 2377
2020
Q2 		$47K Buy
+2,625
New +$44.4K ﹤0.01% 2448
2017
Q4 		– Sell
-10
Closed – – 3602
2017
Q3 		$0 Buy
+10
New +$132 ﹤0.01% 3576

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

US Bancorp's CHRS Position: Q2 2025 in Review

US Bancorp sold out of Coherus Oncology (CHRS) in Q2 2025, closing a stake of 3,001 shares — an estimated $2.42K sold.

US Bancorp first reported a position in CHRS in Q3 2017 and held it in 18 quarters. The position peaked at $75K in Q2 2021. 112 funds tracked by Wall St. Rank hold CHRS as of Q2 2025.

  • US Bancorp reported no remaining Coherus Oncology position as of Q2 2025 after selling out during the quarter.
  • US Bancorp sold 3,001 Coherus Oncology shares in Q2 2025, an estimated $2.42K.
  • US Bancorp first reported a position in Coherus Oncology in Q3 2017 and held it in 18 quarters.
  • US Bancorp's Coherus Oncology position peaked at $75K in Q2 2021.
  • 112 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2025.

Based on US Bancorp's 13F filing for Q2 2025, filed 24 Jul 2025.